Street Calls of the Week
LONDON - Futura Medical plc (AIM:FUM), the company behind erectile dysfunction treatment Eroxon, announced Friday that its revenue for the year ending December 31, 2025, is expected to be "materially below expectations" at between £1.3 million and £1.4 million.
The consumer healthcare company cited slower-than-anticipated in-market sales across all territories, particularly in the United States, where market potential was considered greatest. Initial inventory orders from distributors recognized in 2024 continue to meet current demand, resulting in significantly lower replenishment sales.
Additionally, a $2.5 million milestone payment from Haleon tied to a U.S. patent grant for Eroxon, previously expected in 2025, is now anticipated in the first half of 2026. External legal advice indicates a "high probability" of the patent being granted.
The company reported cash and cash equivalents of £2.71 million at the end of August 2025, which is expected to provide working capital into January 2026. Futura is exploring options to extend its cash runway, including a "significant restructuring" to align its cost base with current commercial progress.
Futura has broadened its ongoing strategic review to consider various options for creating shareholder value, including alternative partnering arrangements for Eroxon and potential sale of one or more business assets. Development plans for Eroxon Intense and WSD4000, a treatment for sexual dysfunction in women, continue to progress.
The company will release its interim results for the six months ended June 30, 2025, on September 30, according to the press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.